ALSO NOTED: Acambis cleared on smallpox vaccine; Regulators OK Arixtra; Celera buys Berkeley HeartLab

> Acambis got the FDA's go-ahead on its smallpox vaccine, a key step in the company's quest for a long-term manufacturing contract with the U.S. government. The company says it's negotiating a deal with the U.S. Centers for Disease Control and Prevention to produce the vaccine here in the U.S.; observers value the deal at around $30 million per year for between five and 10 years. Report

> GlaxoSmithKline got the OK from European regulators to market its anti-clotting drug Arixtra for acute coronary syndromes, which include chest pain and two types of heart attacks. ACS affects about 3 million people worldwide, the company said. Report

> Celera Group says it's agreed to buy Berkeley HeartLab for about $195 million in cash. BHL sells cardiac disease management services, including various blood tests--a business that will complement Celera's genetic markers that identify patients at risk for heart disease and those who'll most benefit from various treatments for it, the company said. Report 

> Novartis has wrapped up its divestment program with the $5.5 billion sale of its Gerber baby foods business to Nestlé. The Swiss pharma has been selling off any units unrelated to healthcare. Release 

And Finally... Whose fault is it that you're too smart for your own good? Thanks to new DNA testing, you may soon find out whether to blame Mom or Dad for your incredible intelligence, breathtaking beauty, or flat feet. Article 

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?